| Popis: |
Although in recent years we have gained a deeper understanding of the pathophysiology of major depressive disorder, this improved understanding has not translated into improved treatment outcomes. Therefore, the screening of putative biological markers may be crucial to facilitate more rapid, successful treatment. Ongoing research has explored the importance of studying physiological biomarkers, including neuroimaging, neurophysiology, genomics, proteomics, and metabolomics, as well as cognition, to gain a better understanding of subtypes of depression and treatment response. However, only through an integrated, multimodal biomarker approach can we truly achieve better outcomes. |
